TickerTalks
Browse all tickers →
TickerTalks›$SCTX
SCSCTX

Scribe Therapeutics Inc.

$SCTX·$350M·Biotechnology·Healthcare
$18.06-4.8%1Y+26.5%
Mentions · last 7 days
2026-07-21: 1 posts2026-07-22: 5 posts2026-07-23: 3 posts2026-07-24: 47 posts2026-07-25: 9 posts2026-07-26: 12 posts2026-07-27: 16 posts93+16%
Price updated 7m ago·X counts updated 22h ago
SCSCTX
$SCTXScribe Therapeutics Inc.
$18.06-4.80%93 posts+16%
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $SCTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellEvent coming upAI verdict · as of 2026-07-27

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Preclinical CRISPR IPO with Sanofi backing at $19 — story is intriguing, financials effectively unknown.

Scribe Therapeutics is a $350M clinical/preclinical CRISPR IPO at $19.19 (IPO priced at $15/share for $128.7M gross on 8.58M shares). T12M +44%. All fundamental fields are null because the company just began public reporting.

What we can say:

  • Sanofi-backed, targeting PCSK9 (cardiovascular) with in-vivo CRISPR — a large unmet market that has already attracted multiple biotech attempts and one FDA approval in the space.
  • Featured as an XBI-basket standout gene-editing IPO in this week's biotech chatter.
  • Only one news item and no filings in the bundle — coverage is thin because listing is recent.

Nothing else material to say without a first quarterly report, cash-runway disclosure, or a Ph1 dose-finding readout. Today's -11% print is IPO-window volatility, not signal about the science.

This is a name to watch for the first 10-K/10-Q + any preclinical-to-Ph1 milestone, not to underwrite based on the current data. Everything about the trade is optionality on the platform and Sanofi partnership.

What to watch: First 10-Q (cash runway), any Ph1 IND timing, and any Sanofi-collaboration progress disclosures.

recent ipopreclinical stagesanofi backedthin disclosure

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-07-27

Scribe Therapeutics priced an upsized IPO of approximately 8.58 million shares at $15/share for gross proceeds of $128.7M. The Sanofi-backed preclinical CRISPR gene-editing company targets the underserved PCSK9 cardiovascular market. Contributors welcome the new listing to Nasdaq as needed positive IPO news for the biotech complex.

Read the AI verdict + X sentiment for $SCTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SCTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.0%YTD
+40.4%1Y

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.—Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.—Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placementglobenewswire.com·1d agoScribe Therapeutics Announces Pricing of Upsized Initial Public Offeringglobenewswire.com·5d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$SLS$MRNA$ABVX$CAPR$ALLO$IBRX$ARWR
Voices on X · top 8 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport